Connect your AI

Schrodinger SDGR Drug discovery — Milestone payment yet to be achieved

Similar metrics at other companies

TARSDevelopment and Regulatory Milestone — Milestone payments to be achieved

$67.5M0.0%

DNTHMilestone — Revenue Recognition Milestone Method Pending

$15M0.0%

AMRXAffordable Medicines — Milestones

$500K+100%

TARSDevelopment and Regulatory Milestone — Maximum milestone payments

$20M0.0%

INVAResearch And Development Support — Future Potential Milestone Payment

$91M0.0%

INSMPayment Of Milestone

$15M—

Other financials

Income statement

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

Market cap$1.15B-23.7%

Enterprise value$984.71M-23.1%

P/S4.5×-2.0×

Profitability

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept sdgr:MilestonePaymentYetToBeAchieved.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's drug discovery — milestone payment yet to be achieved.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Schrodinger's drug discovery — milestone payment yet to be achieved?: Schrodinger (SDGR) reported drug discovery — milestone payment yet to be achieved of $0 in Q1 2026.
What does drug discovery — milestone payment yet to be achieved mean?: This captures the value of future potential payments tied to specific research or clinical development milestones that have not yet been met. It acts as a leading indicator for potential future revenue streams and the progress of the drug discovery pipeline.